Baseline Testosterone Predicts Body Composition and Metabolic Response to Testosterone Therapy

Area of Science:

• Endocrinology
• Men's Health
• Metabolic Health

Background:

• Male hypogonadism negatively impacts body composition, bone mineral density (BMD), and metabolic health.
• Previous research indicated lower baseline testosterone (<200 ng/dl) predicts greater spine BMD improvement with testosterone therapy.
• The influence of baseline testosterone levels on body composition and metabolic response to therapy remained uninvestigated.

Purpose of the Study:

• To compare changes in body composition, metabolic profile, and bone turnover markers in response to testosterone therapy.
• To determine if baseline testosterone levels (<264 ng/dl vs. ≥264 ng/dl) influence these outcomes.

Main Methods:

• Secondary analysis of a single-arm, open-label clinical trial (NCT01378299) involving 105 men (40-74 years) with average morning testosterone < 300 ng/dl.
• Participants received intramuscular testosterone cypionate 200 mg every 2 weeks for 18 months.
• Grouped by baseline testosterone: <264 ng/dl (N=43) and ≥264 ng/dl (N=57). Measured BMD, body composition (DXA), HbA1c, glucose, lipids, and hormones.

Main Results:

• Men with baseline testosterone < 264 ng/dl exhibited greater increases in total fat-free mass (FFM) and appendicular FFM at 6 and 18 months.
• Men with baseline testosterone ≥ 264 ng/dl showed significant improvements in HbA1c, fasting glucose, LDL, and leptin.
• No significant differences in BMD or bone turnover markers were observed between groups.

Conclusions:

• Testosterone therapy improves body composition regardless of baseline testosterone levels.
• Baseline testosterone < 264 ng/dl is associated with superior FFM gains.
• Baseline testosterone ≥ 264 ng/dl favors improvements in metabolic parameters.